Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ana M. Arance Fernandez"'
Autor:
James Larkin, Michele Del Vecchio, Mario Mandalá, Helen Gogas, Ana M. Arance Fernandez, Stéphane Dalle, Charles Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion-Sileni, Ivan Marquez-Rodas, Marcus O. Butler, Anna Maria Di Giacomo, Mark R. Middleton, Jose Lutzky, Luis de la Cruz-Merino, Petr Arenberger, Victoria Atkinson, Andrew G. Hill, Leslie A. Fecher, Michael Millward, Paul D. Nathan, Nikhil I. Khushalani, Paola Queirolo, Corey Ritchings, Maurice Lobo, Margarita Askelson, Hao Tang, Sonia Dolfi, Paolo A. Ascierto, Jeffrey Weber
Publikováno v:
Clinical Cancer Research. :OF1-OF10
Purpose: In the phase III CheckMate 238 study, adjuvant nivolumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival versus ipilimumab in patients with resected stage IIIB–C or stage IV melanoma, with benefit
Autor:
Jeffrey Weber, Paolo A. Ascierto, Sonia Dolfi, Hao Tang, Margarita Askelson, Maurice Lobo, Corey Ritchings, Paola Queirolo, Nikhil I. Khushalani, Paul D. Nathan, Michael Millward, Leslie A. Fecher, Andrew G. Hill, Victoria Atkinson, Petr Arenberger, Luis de la Cruz-Merino, Jose Lutzky, Mark R. Middleton, Anna Maria Di Giacomo, Marcus O. Butler, Ivan Marquez-Rodas, Vanna Chiarion-Sileni, Jean-Jacques Grob, Michael Schenker, Charles Lance Cowey, Stéphane Dalle, Ana M. Arance Fernandez, Helen Gogas, Mario Mandalá, Michele Del Vecchio, James Larkin
DATA SUPPLEMENT Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52cb1057ddae601989ec0e00460b71a9
https://doi.org/10.1158/1078-0432.22787545.v1
https://doi.org/10.1158/1078-0432.22787545.v1
Autor:
Jeffrey Weber, Paolo A. Ascierto, Sonia Dolfi, Hao Tang, Margarita Askelson, Maurice Lobo, Corey Ritchings, Paola Queirolo, Nikhil I. Khushalani, Paul D. Nathan, Michael Millward, Leslie A. Fecher, Andrew G. Hill, Victoria Atkinson, Petr Arenberger, Luis de la Cruz-Merino, Jose Lutzky, Mark R. Middleton, Anna Maria Di Giacomo, Marcus O. Butler, Ivan Marquez-Rodas, Vanna Chiarion-Sileni, Jean-Jacques Grob, Michael Schenker, Charles Lance Cowey, Stéphane Dalle, Ana M. Arance Fernandez, Helen Gogas, Mario Mandalá, Michele Del Vecchio, James Larkin
Purpose:In the phase III CheckMate 238 study, adjuvant nivolumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival versus ipilimumab in patients with resected stage IIIB–C or stage IV melanoma, with benefit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30007277e80b61bdf1c2ca6cbcc13787
https://doi.org/10.1158/1078-0432.c.6637744.v1
https://doi.org/10.1158/1078-0432.c.6637744.v1